No more monoclonal antibody treatments for Covid are available in the U.S.: The Food and Drug Administration on Wednesday rescinded its authorization of bebtelovimab, a drug previously given to patients who faced a high risk of severe disease.

Over the last two years, the FDA authorized six monoclonal antibody treatments for Covid, but omicron’s many subvariants rendered the drugs less effective so the FDA gradually revoked each of those authorizations. Bebtelovimab, made by Eli Lilly, was the last one standing.

According to the FDA’s announcement, the drug was “not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1.,” which together now account for the majority of new infections recorded in the U.S. — around 62%, data from the Centers for Disease Control and Prevention show.

“The big problem is that monoclonal antibodies bind to a very small piece of the virus. As the virus changes, we are now in a position in which we lost them all because they don’t bind to the virus anymore,” said Dr. Arturo Casadevall, a professor of medicine at the Johns Hopkins School of Medicine.

Paxlovid has become the go-to treatment for most people at high risk of severe Covid,

 » …


Continue To Full Article